CureMab

CureMab is a South Korean biotechnology company specializing in the discovery and development of therapeutic monoclonal antibodies for oncology. The company utilizes its proprietary antibody engineering platform to create high-affinity candidates that target validated pathways involved in tumor growth and resistance, such as c-Met and EGFR. Its lead candidate, CU001, is a humanized anti-c-Met monoclonal antibody currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. CureMab's pipeline also includes several preclinical programs targeting VEGF and PD-L1, aiming to provide novel treatment options for patients with limited therapeutic alternatives. The company is focused on advancing its internal programs while seeking strategic global partnerships for co-development and commercialization.